Previous 10 | Next 10 |
2024-02-05 07:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
ROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics...
ROCKVILLE, Md., and SYDNEY, Australia, Jan. 23, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based th...
2024-01-09 16:20:04 ET Gainers: WISeKey International ( WKEY ) +14% . MaxCyte ( MXCT ) +8% . Humacyte. ( HUMA ) +8% . Agora ( API ) +6% . Urban Outfitters ( URBN ) +6% . Losers: Grifols ( GRFS ) -9% . Ex...
2024-01-08 16:53:20 ET Gainers: Universe Pharmaceuticals ( UPC ) +13% . MaxCyte ( MXCT ) +12% . WISeKey International Holding ( WKEY ) +8% . Alset Capital Acquisition ( ACAX ) +7% . Atea Pharmaceuticals ( AVIR ) +...
2024-01-08 16:36:57 ET More on MaxCyte MaxCyte May Benefit From Potential Gene Therapy Approval MaxCyte announces departure of founder and CEO Doug Doerfler Gene editing stocks mixed despite world’s first CRISPR drug approval Seeking Alpha’s Qua...
ROCKVILLE, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioproce...
2024-01-03 10:22:28 ET More on MaxCyte MaxCyte May Benefit From Potential Gene Therapy Approval MaxCyte announces departure of founder and CEO Doug Doerfler Gene editing stocks mixed despite world’s first CRISPR drug approval For further details see: ...
ROCKVILLE, Md. and SINGAPORE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and ...
2024-01-02 05:27:10 ET More on MaxCyte MaxCyte May Benefit From Potential Gene Therapy Approval MaxCyte announces departure of founder and CEO Doug Doerfler Seeking Alpha’s Quant Rating on MaxCyte For further details see: MaxCyte gets new CEO and P...
News, Short Squeeze, Breakout and More Instantly...
MaxCyte Inc. Company Name:
MXCT Stock Symbol:
NASDAQ Market:
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providi...
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioproc...
ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovat...